2021
2 December, 2021
Publication in The New England Journal of Medicine Confirms that Tens of Thousands of Women with Node-positive, Early-stage Breast Cancer Can Avoid Chemotherapy with the Oncotype DX® Test
20 May, 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer
25 March, 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer
2020
9 December, 2020
RxPONDER study results demonstrate that the Oncotype DX® Test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer
2 October, 2020
New real-world evidence further demonstrates the Oncotype DX Breast Recurrence Score® Test’s clinical utility, beyond clinical risk factors, in guiding chemotherapy treatment decisions in patients with early-stage breast cancer
29 May, 2020
New data and society guidelines support value of Oncotype DX Breast Recurrence Score® Test in guiding neoadjuvant treatment decisions for newly diagnosed patients
14 May, 2020
New Oncotype DX® real-world evidence shows for the first time the practice-changing impact of TAILORx results
2019
12 December, 2019
New Evidence from Large Studies Highlights Value of Oncotype DX Breast Recurrence Score to Guide Chemotherapy Treatment in Young Patients with Node-negative or Node-positive Early-stage Breast Cancer
2 October, 2019
New TAILORx Data, Published in JAMA Oncology, Add to Strong Evidence Base Reinforcing Unique Ability of Oncotype DX Breast Recurrence Score Test to Guide Chemotherapy Treatment
21 June, 2019
German Federal Joint Committee (G-BA) Issues Exclusive Nationwide Reimbursement Decision for Oncotype DX Breast Recurrence Score Test
4 June, 2019
Secondary Analysis of Landmark TAILORx Results, Published in The New England Journal of Medicine, Affirms Unique Ability of Oncotype DX Breast Recurrence Score Test to Predict Chemotherapy Benefit, Guiding Adjuvant Therapy with Even Greater Precision
25 March, 2019
Evidence from UK hospitals supports the value of the Oncotype DX test in avoiding unnecessary chemotherapy for patients with node-positive breast cancer
2018
19 December, 2018
NICE expands recommendation for the Oncotype DX test to more patients with early-stage breast cancer
11 December, 2018
New long-term evidence from large study reinforces value of the Oncotype DX Breast Recurrence Score test to guide adjuvant chemotherapy treatment, confirming TAILORx conclusions
22 October, 2018
New real-world evidence confirms value of the Oncotype DX test in clinical practice for patients with early-stage breast cancer
3 June, 2018
Landmark TAILORx Results, Published Today in The New England Journal of Medicine, Demonstrate the Oncotype DX Breast Recurrence Score Test Definitively Identifies the 70% of Women with Early-stage Breast Cancer Who Receive No Benefit from Chemotherapy, and the 30% of Women for Whom Chemotherapy Benefit Can be Life-saving
2017
11 December, 2017
New results from large registry with 10-year follow up show excellent outcomes for patients with low Oncotype DX Breast Recurrence Score® results treated with hormonal therapy alone
11 September, 2017
Genomic test shows that half of under-40s with early breast cancer have excellent prognosis despite not having chemotherapy treatment
12 July, 2017
Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer
13 June, 2017
New data show important role of genomic testing in treatment of older breast cancer patients
20 March, 2017
Genomic Health’s Oncotype DX breast cancer test can significantly improve patient outcomes for node-positive patients, international studies reveal
6 February, 2017
NHS adoption of Oncotype DX test leads to substantial reduction in unnecessary chemotherapy for UK breast cancer patients
2016
12 December, 2016
New data demonstrate that Oncotype DX can help guide treatment decisions before breast cancer surgery enabling more personalised care, including avoidance of full mastectomy
10 October, 2016
Updated St. Gallen International Breast Cancer Guidelines reinforce important role of genomic testing in treatment of early breast cancer
20 June, 2016
Updated NICE quality standard recommends Oncotype DX® in early-stage breast cancer
6 June, 2016
Oncotype DX presentations at 2016 ASCO® annual meeting reinforce Genomic Health’s leadership in optimising breast cancer treatment
31 May, 2016
Innovative Oncotype DX test available in centres throughout West of Scotland Cancer Network to guide treatment decisions for early breast cancer patients
11 March, 2016
Five-year outcomes results from European ‘PlanB’ study show that breast cancer patients with low Oncotype DX Recurrence Score® results can be spared chemotherapy despite having high-risk disease by traditional measures
